![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TUBB6 |
Gene summary for TUBB6 |
![]() |
Gene information | Species | Human | Gene symbol | TUBB6 | Gene ID | 84617 |
Gene name | tubulin beta 6 class V | |
Gene Alias | FPVEPD | |
Cytomap | 18p11.21 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q9BUF5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84617 | TUBB6 | PTC07 | Human | Thyroid | PTC | 4.23e-21 | 4.04e-01 | 0.2044 |
84617 | TUBB6 | ATC09 | Human | Thyroid | ATC | 1.74e-23 | 1.33e+00 | 0.2871 |
84617 | TUBB6 | ATC11 | Human | Thyroid | ATC | 1.03e-14 | 1.61e+00 | 0.3386 |
84617 | TUBB6 | ATC12 | Human | Thyroid | ATC | 1.00e-34 | 8.81e-01 | 0.34 |
84617 | TUBB6 | ATC13 | Human | Thyroid | ATC | 1.49e-39 | 9.40e-01 | 0.34 |
84617 | TUBB6 | ATC1 | Human | Thyroid | ATC | 9.31e-27 | 1.54e+00 | 0.2878 |
84617 | TUBB6 | ATC2 | Human | Thyroid | ATC | 2.96e-16 | 1.84e+00 | 0.34 |
84617 | TUBB6 | ATC3 | Human | Thyroid | ATC | 4.95e-15 | 1.00e+00 | 0.338 |
84617 | TUBB6 | ATC4 | Human | Thyroid | ATC | 4.37e-41 | 1.16e+00 | 0.34 |
84617 | TUBB6 | ATC5 | Human | Thyroid | ATC | 6.13e-44 | 1.10e+00 | 0.34 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05012211 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa05020210 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0414530 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05012310 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa0502038 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04145114 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
hsa0501428 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa0501230 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TUBB6 | SNV | Missense_Mutation | rs763504507 | c.1172G>A | p.Arg391His | p.R391H | Q9BUF5 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.96) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
TUBB6 | SNV | Missense_Mutation | c.935N>T | p.Thr312Ile | p.T312I | Q9BUF5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TUBB6 | SNV | Missense_Mutation | c.730N>T | p.Gly244Cys | p.G244C | Q9BUF5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-AA-3680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | PD | |
TUBB6 | SNV | Missense_Mutation | novel | c.418N>C | p.Gly140Arg | p.G140R | Q9BUF5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
TUBB6 | SNV | Missense_Mutation | rs756545880 | c.751N>T | p.Arg251Cys | p.R251C | Q9BUF5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TUBB6 | SNV | Missense_Mutation | novel | c.1194N>A | p.Phe398Leu | p.F398L | Q9BUF5 | protein_coding | deleterious_low_confidence(0) | benign(0.054) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
TUBB6 | SNV | Missense_Mutation | novel | c.130N>A | p.Leu44Met | p.L44M | Q9BUF5 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.866) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
TUBB6 | SNV | Missense_Mutation | novel | c.1091N>T | p.Ala364Val | p.A364V | Q9BUF5 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.642) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
TUBB6 | SNV | Missense_Mutation | rs777748559 | c.990N>A | p.Met330Ile | p.M330I | Q9BUF5 | protein_coding | tolerated_low_confidence(0.09) | benign(0.121) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TUBB6 | SNV | Missense_Mutation | novel | c.611A>G | p.Asn204Ser | p.N204S | Q9BUF5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.906) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
84617 | TUBB6 | DRUGGABLE GENOME | inhibitor | CHEMBL1742994 | BRENTUXIMAB VEDOTIN | |
84617 | TUBB6 | DRUGGABLE GENOME | COLCHICINE | COLCHICINE | 23750455,25805446,24502232,25061803,25937236,24773591,25938266 | |
84617 | TUBB6 | DRUGGABLE GENOME | inhibitor | CHEMBL289351 | FOSBRETABULIN DISODIUM | |
84617 | TUBB6 | DRUGGABLE GENOME | CYCLOSTREPTIN | CYCLOSTREPTIN | 17206139 | |
84617 | TUBB6 | DRUGGABLE GENOME | inhibitor | CHEMBL552212 | LEXIBULIN | |
84617 | TUBB6 | DRUGGABLE GENOME | VINBLASTINE | VINBLASTINE | 23708010,23916255 | |
84617 | TUBB6 | DRUGGABLE GENOME | CHEMBL492399 | VERUBULIN | ||
84617 | TUBB6 | DRUGGABLE GENOME | inhibitor | CHEMBL1201752 | IXABEPILONE | |
84617 | TUBB6 | DRUGGABLE GENOME | PACLITAXEL | PACLITAXEL | 23631389,25369367,25768699,24457094,22595423,23313639,17887662,23387901,19758808,23725535,24953821 | |
84617 | TUBB6 | DRUGGABLE GENOME | CHEMBL2304041 | SAGOPILONE |
Page: 1 2 3 4 5 |